Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease characterized by joint inflammation, structural damage, and associated skin manifestations of psoriasis. Despite the availability of several biologic and targeted therapies, many patients continue to experience persistent disease activity or treatment intolerance, highlighting the need for additional therapeutic options. Deucravacitinib (Sotyktu), an oral selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb, has now received approval from the U.S. Food and Drug Administration for the treatment of adults with active psoriatic arthritis. This approval represents the first TYK2 inhibitor authorized for this indication and introduces a novel mechanism targeting intracellular cytokine signaling pathways involved in immune-mediated inflammation.
The regulatory decision was based on results from the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 randomized, double-blind, placebo-controlled trials evaluating deucravacitinib 6 mg administered once daily in adults with active PsA. Across both studies, the therapy demonstrated significant improvements in disease activity compared with placebo at Week 16. The primary endpoint—achievement of an American College of Rheumatology 20% improvement response (ACR20)—was met, with approximately 54% of patients receiving deucravacitinib achieving ACR20 compared with 34%–39% in the placebo groups. Higher-level responses such as ACR50 and ACR70 were also more frequently observed among treated patients.
In addition to improvements in joint symptoms, patients treated with deucravacitinib showed enhanced rates of minimal disease activity (MDA), indicating broader control of disease manifestations including pain, swelling, and functional limitations. The overall safety profile observed in the Phase 3 trials was consistent with earlier studies and demonstrated acceptable tolerability, with no new safety signals reported during the evaluation period.
Deucravacitinib acts through selective allosteric inhibition of TYK2, a member of the Janus kinase family involved in signaling pathways for key cytokines such as interleukin-23 and type I interferons. This targeted mechanism allows modulation of inflammatory pathways implicated in psoriatic disease while maintaining selectivity that may differentiate it from broader JAK inhibitors. With this approval, deucravacitinib provides a convenient once-daily oral treatment option for patients with active psoriatic arthritis. The therapy expands the available treatment landscape and offers a mechanistically distinct alternative that may help improve disease control and quality of life in individuals living with PsA.
